[breadcrumb_custom]

Kintara Therapeutics Inc (NASDAQ: KTRA) Stock’s Potential for Success in the Coming Months

In the last trading session, 3.16 million Kintara Therapeutics Inc (NASDAQ:KTRA) shares changed hands as the company’s beta touched 0.63. With the company’s per share price at $0.12 changed hands at $0.0 or 2.05% during last session, the market valuation stood at $0.42M. KTRA’s last price was a discount, traded about -5416.67% off its 52-week high of $6.62. The share price had its 52-week low at $0.11, which suggests the last value was 8.33% up since then. When we look at Kintara Therapeutics Inc’s average trading volume, we note the 10-day average is 5.25 million shares, with the 3-month average coming to 0.47.

Kintara Therapeutics Inc (NASDAQ:KTRA) trade information

Instantly KTRA was in green as seen at the end of in last trading. With action -0.32%, the performance over the past five days has been red. The jump to weekly highs of 0.1303 added 2.05% to the stock’s daily price. The company’s shares are showing year-to-date downside of -26.59%, with the 5-day performance at -0.32% in the red. However, in the 30-day time frame, Kintara Therapeutics Inc (NASDAQ:KTRA) is -15.25% down. Looking at the short shares, we see there were 0.16 million shares sold at short interest cover period of 0.02 days.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Kintara Therapeutics Inc (KTRA) estimates and forecasts

Data shows that the Kintara Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -96.75% over the past 6 months, a 95.15% in annual growth rate that is considerably higher than the industry average of 15.50%.

Kintara Therapeutics Inc (NASDAQ:KTRA)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 2.40% of Kintara Therapeutics Inc shares while 2.72% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 2.79%. There are 2.72% institutions holding the Kintara Therapeutics Inc stock share, with Geode Capital Management, LLC the top institutional holder. As of Jun 29, 2023, the company held 0.80% of the shares, roughly 14036.0 KTRA shares worth $56565.0.

State Street Corporation holds the second largest percentage of outstanding shares, with 0.61% or 10721.0 shares worth $43205.0 as of Jun 29, 2023.

Among Mutual Funds, the top two as of May 30, 2023 were Fidelity Extended Market Index Fund and Vanguard Extended Market Index Fund. With 9104.0 shares estimated at $29223.0 under it, the former controlled 0.52% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.43% of the shares, roughly 7563.0 shares worth around $30478.0.

On Key

Related Posts